Difference between revisions of "Template:Antithrombotics"

From blackwiki
Jump to navigation Jump to search
blackwiki>Anypodetos
m (Restore title)
blackwiki>Diannaa
(improve mark-up)
Line 2: Line 2:
 
| name  = Antithrombotics
 
| name  = Antithrombotics
 
| title = [[Antithrombotic]]s ([[thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]])
 
| title = [[Antithrombotic]]s ([[thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]])
|listclass = hlist
+
| listclass = hlist
* [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]])
+
| groupstyle = background:MistyRose;
| groupstyle = background:MistyRose;  
 
  
 
| group1 = [[Antiplatelet drug]]s
 
| group1 = [[Antiplatelet drug]]s
Line 18: Line 17:
 
| group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]]
 
| group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]]
 
|  list2 =
 
|  list2 =
* ''[[thienopyridine]]s'' ([[Clopidogrel]]
+
* ''[[thienopyridine]]s''
* [[Prasugrel]]
+
** [[Clopidogrel]]
* [[Ticlopidine]])
+
** [[Prasugrel]]
* ''[[nucleotide]]/[[nucleoside]] analogs'' ([[Cangrelor]]
+
** [[Ticlopidine]]
* [[Elinogrel]]
+
* ''[[nucleotide]]/[[nucleoside]] analogs''
* [[Ticagrelor]])
+
** [[Cangrelor]]
 +
** [[Elinogrel]]
 +
** [[Ticagrelor]]
  
 
| group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]])
 
| group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]])
Line 42: Line 43:
 
| group5 = [[Thromboxane inhibitors]]
 
| group5 = [[Thromboxane inhibitors]]
 
|  list5 =
 
|  list5 =
* ''[[thromboxane synthase inhibitors]]'' ([[Dipyridamole]]
+
* ''[[thromboxane synthase inhibitors]]''
* [[Picotamide]])
+
** [[Dipyridamole]]
* ''[[Thromboxane receptor antagonist|receptor antagonist]]'' ([[Terutroban]]<sup>†</sup>)
+
** [[Picotamide]]
 +
 
 +
* ''[[Thromboxane receptor antagonist|receptor antagonist]]''
 +
** [[Terutroban]]<sup>†</sup>
  
 
| group6 = [[Phosphodiesterase inhibitor]]s
 
| group6 = [[Phosphodiesterase inhibitor]]s
Line 52: Line 56:
 
* [[Triflusal]]
 
* [[Triflusal]]
  
| group7 = Other  
+
| group7 = Other
 
|  list7 =
 
|  list7 =
 
* [[Cloricromen]]
 
* [[Cloricromen]]
 
* [[Ditazole]]
 
* [[Ditazole]]
 
 
}}
 
}}
  
Line 76: Line 79:
 
* [[Phenindione]]
 
* [[Phenindione]]
  
''other:'' [[Tioclomarol]]  
+
* ''other:'' [[Tioclomarol]]
  
 
| group2 = [[Factor Xa]] inhibitors<br />(with some II inhibition)
 
| group2 = [[Factor Xa]] inhibitors<br />(with some II inhibition)
Line 84: Line 87:
 
| group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]])
 
| group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]])
 
| list1  =
 
| list1  =
* ''[[low-molecular-weight heparin]]'' ([[Bemiparin sodium|Bemiparin]]
+
* ''[[low-molecular-weight heparin]]''
* [[Certoparin sodium|Certoparin]]
+
** [[Bemiparin sodium|Bemiparin]]
* [[Dalteparin sodium|Dalteparin]]
+
** [[Certoparin sodium|Certoparin]]
* [[Enoxaparin sodium|Enoxaparin]]
+
** [[Dalteparin sodium|Dalteparin]]
* [[Nadroparin calcium|Nadroparin]]
+
** [[Enoxaparin sodium|Enoxaparin]]
* [[Parnaparin sodium|Parnaparin]]
+
** [[Nadroparin calcium|Nadroparin]]
* [[Reviparin sodium|Reviparin]]
+
** [[Parnaparin sodium|Parnaparin]]
* [[Tinzaparin sodium|Tinzaparin]])
+
** [[Reviparin sodium|Reviparin]]
 +
** [[Tinzaparin sodium|Tinzaparin]]
  
*''[[oligosaccharide]]s'' ([[Fondaparinux]]
+
* ''[[oligosaccharide]]s''
* [[Idraparinux]])
+
** [[Fondaparinux]]
 +
** [[Idraparinux]]
  
*''[[heparinoid]]'' ([[Danaparoid]]
+
* ''[[heparinoid]]''
* [[Sulodexide]]
+
** [[Danaparoid]]
* [[Dermatan sulfate]])
+
** [[Sulodexide]]
 +
** [[Dermatan sulfate]]
  
 
| group7 = [[Direct Xa inhibitor]]s
 
| group7 = [[Direct Xa inhibitor]]s
 
|  list7 =
 
|  list7 =
* ''xabans'' ([[Apixaban]]
+
* ''xabans''
* [[Betrixaban]]
+
** [[Apixaban]]
 +
** [[Betrixaban]]
 
* [[Edoxaban]]
 
* [[Edoxaban]]
* [[Otamixaban]]
+
** [[Otamixaban]]
* [[Rivaroxaban]])
+
** [[Rivaroxaban]]
 
 
 
}}
 
}}
  
 
| group6 = [[Direct thrombin inhibitor|Direct thrombin (II) inhibitor]]s
 
| group6 = [[Direct thrombin inhibitor|Direct thrombin (II) inhibitor]]s
 
|  list6 =
 
|  list6 =
* ''[[Direct_thrombin_inhibitor#Bivalent|bivalent]]:'' [[Hirudin]] ([[Bivalirudin]]
+
* ''[[Direct_thrombin_inhibitor#Bivalent|bivalent]]:'' [[Hirudin]]
* [[Lepirudin]]
+
** [[Bivalirudin]]
* [[Desirudin]])<br />
+
** [[Lepirudin]]
 +
** [[Desirudin]]
  
*''[[Direct_thrombin_inhibitor#Univalent|univalent]]:'' [[Argatroban]]
+
* ''[[Direct_thrombin_inhibitor#Univalent|univalent]]:'' [[Argatroban]]
 
* [[Dabigatran]]
 
* [[Dabigatran]]
 
* [[Melagatran]]<sup>‡</sup>
 
* [[Melagatran]]<sup>‡</sup>
 
* [[Ximelagatran]]<sup>‡</sup>
 
* [[Ximelagatran]]<sup>‡</sup>
  
| group8 = Other  
+
| group8 = Other
 
|  list8 =
 
|  list8 =
 
* [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]]
 
* [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]]
Line 127: Line 134:
 
* [[Ramatroban]]
 
* [[Ramatroban]]
 
* [[Antithrombin|Antithrombin III]]
 
* [[Antithrombin|Antithrombin III]]
* [[Protein C]] ([[Drotrecogin alfa]])
+
* [[Protein C]]
 
+
** [[Drotrecogin alfa]]
 
}}
 
}}
  
 
| group5 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s
 
| group5 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s
 
|  list5 =
 
|  list5 =
* ''[[plasminogen activator]]s:'' ''[[recombinant tissue plasminogen activators|r-tPA]]'' ([[Tissue plasminogen activator|Alteplase]]
+
* ''[[plasminogen activator]]s:'' ''[[recombinant tissue plasminogen activators|r-tPA]]''
* [[Reteplase]]
+
** [[Tissue plasminogen activator|Alteplase]]
* [[Tenecteplase]])
+
** [[Reteplase]]
* ''UPA'' ([[Urokinase]]
+
** [[Tenecteplase]]
* [[Saruplase]])
+
* ''UPA''
 +
** [[Urokinase]]
 +
** [[Saruplase]]
 
* [[Streptokinase]]<sup>#</sup>
 
* [[Streptokinase]]<sup>#</sup>
 
* [[Anistreplase]]
 
* [[Anistreplase]]
Line 145: Line 154:
 
* [[Fibrinolysin]]
 
* [[Fibrinolysin]]
 
* [[Brinase]]
 
* [[Brinase]]
 
  
 
| group8 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]]
 
| group8 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]]
Line 152: Line 160:
 
* [[EDTA]]
 
* [[EDTA]]
 
* [[Oxalate]]
 
* [[Oxalate]]
 
| group9 =
 
| list9  =
 
  
 
| belowstyle = background: transparent; padding: 0px;
 
| belowstyle = background: transparent; padding: 0px;

Revision as of 19:04, 2 June 2012